Skip navigation

Stay Ahead of Impactful Changes to Your Medicare Strategy

August 21, 2018
  • Arlington, VA

CBI’s Bio/Pharma Forum on The State of Medicare Reform is focused on the current healthcare landscape and proposed changes and implications of Trump’s Blueprint. It is critical that pharmaceutical and biotech manufacturers keep abreast of how the changing healthcare and insurance landscape will impact Medicare strategy.

Attend this elite meeting to stay on the cutting-edge of information related to Medicare Part B and D and gain an early outlook to understand the major impact of the proposed changes and implications of Trump’s Blueprint.

Critical Topics for Discussion Include:

  • Discuss the overview of proposed legislative changes to Medicare Part B and D
  • Gain an update from Washington on the ripple effect of Medicare reform
  • Hear from industry experts on the implications of Trump’s Blueprint
  • Examine the changes to the Coverage Gap liability
  • Address the proposal to share drug rebates more
    directly with patients at the point of sale
  • Discuss the potential impact of transitioning Medicare Part B covered drugs to Part D
  • Assess the recent changes to Medicare’s payment rate for certain Medicare Part B drugs purchased through the 340B program
  • Learn about the industry perception of co-pay accumulator programs for specialty drugs